STABILITY – Hypertension Trial

Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial European Heart Journal (2017)  doi:10.1093/eurheartj/ehx250 Objective:  To study the relation between visit-to-visit variability of blood pressure (BP) and long term cardiovascular risk in patients with stable coronary heart disease. Methods: STABILITY trial was a multicentre, […]

Dual Antiplatelet TOPIC study

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study   European Heart Journal (2017)  doi:10.1093/eurheartj/ehx175 Objective: To evaluate the benefit of switching dual antiplatelet therapy (DAPT) from aspirin plus a newer P2Y12 blocker (ticagrelor/prasugrel) to aspirin plus clopidogrel 1 month after ACS. Methods: […]

Dr Vivek Baliga – The Strong Heart Study

Dr Vivek Baliga discusses the latest STRONG heart study in brief. Objective: To evaluate effect of combined high triglycerides (TG) and Low HDL-C on CV risk in American Indians, who have a high prevalence of obesity and diabetes, Methods: 3,216 participants  who were free of cardiovascular disease at baseline in a community-based, prospective cohort of […]

Dr Vivek Baliga – ONTARGET and TRANSCEND studies Synopsis

Synopsis by Dr Vivek Baliga Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies Diabetologia 2014;57:2019–2029  Preamble  Urinary albumin excretion is a strong predictor of cardiovascular disease It is uncertain whether improvement from microalbuminuria or deterioration from normoalbuminuria over time in […]

Dr Vivek Baliga – The role of inflammation in pathogenesis of hypertension

Article by Dr Vivek Baliga This is a nine-year repeated measures data analysis prospective cohort study that was presented at the American Heart Association scientific sessions 2016. The underlying hypothesis for the study was that inflammation affects the development of hypertension through changes in the blood vessel or in renal pathophysiology. The study was a […]

Dr Vivek Baliga – What is the optimum blood pressure target in patients with acute myocardial infarction

Article by Dr Vivek Baliga Recently, a paper was presented at the American Heart Association scientific Sessions in New Orleans that discussed optimal blood pressure target in patients in acute myocardial infarction. The aim of the study was to analyse what the optimal systolic and diastolic BP targets must be in patients who suffer from […]

CCB in Hypertension – Presentation by Dr Vivek Baliga

Calcium channel blockers are commonly used drugs in the treatment of hypertension. They are effective in treating early hypertension though there are some concerns about edema. Here, Dr Vivek Baliga discusses the role of newer calcium channel blockers in the treatment of hypertension. Calcium Channel Blockers in Hypertension from Dr Vivek Baliga Recommended reading Use […]